Skyhawk’s novel approach corrects the underlying genetics of disease at the mRNA level, in the nucleus of the cell. Our drugs can target major neurological conditions, targets previously considered undruggable, such as master transcriptional factors in cancer and a host of targets in immunology, inflammation and infectious diseases.
Skyhawk small molecules
Our SkySTAR* (Skyhawk Small molecule Therapeutics for Alternative splicing in RNA) platform integrates information from computational, kinetic, & structural models of RNA
CONFORMATIONAL STRUCTURAL MODELS
Generating unique and selective families of chemistry for each target
Our focused libraries are then tested in patient cells using proprietary assays, to quickly yield potent drug candidates
PROPRIETARY ASSAYS IN PATIENT CELL LINES
PROPRIETARY SPLICING MODELS
Our current pipeline includes oncology and neurology targets.